BR0014615A - Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b - Google Patents
Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase bInfo
- Publication number
- BR0014615A BR0014615A BR0014615-3A BR0014615A BR0014615A BR 0014615 A BR0014615 A BR 0014615A BR 0014615 A BR0014615 A BR 0014615A BR 0014615 A BR0014615 A BR 0014615A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- alkyl group
- hydrogen atom
- activity against
- represent
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 102000003670 Carboxypeptidase B Human genes 0.000 title abstract 2
- 108090000087 Carboxypeptidase B Proteins 0.000 title abstract 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical class OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4018—Esters of cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
"DERIVADO DE áCIDO FOSFÈNICO QUE APRESENTA ATIVIDADE INIBIDORA CONTRA CARBOXIPEPTIDASE B". Caracterizado pelo fato de compreender um composto representado pela Fórmula Geral ( I ) a seguir e um de seus sais farmacologicamente aceitáveis: em que R^ 1^ representa um átomo de hidrogênio, um grupo alquila, um grupo alquila substituído e similares; R^ 2^ e R^ 3^ representam um átomo de hidrogênio, um grupo alquila, um grupo alquila substituído, um grupo alcoxila e similares; X representa -CH~ 2~-, -O- ou -NH-; A representa o seguinte grupo ( II ): [ em que R^ 7^ e R^ 8^ representam um átomo de hidrogênio, um grupo alquila, um grupo acila, um grupo alcoxicarbonila e similares; R^ 9^ e R^ 10^ representam um átomo de hidrogênio, um átomo de halogênio, um grupo hidroxila, um grupo fenila, um grupo alquila e similares ] e similares; e E representa um átomo de hidrogênio e similares, que apresenta atividade inibidora contra carboxipeptidase B e é útil para o tratamento terapêutico e/ou preventivo de uma doença trombótica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26099399 | 1999-09-14 | ||
JP2000084145 | 2000-03-24 | ||
PCT/JP2000/006248 WO2001019836A1 (fr) | 1999-09-14 | 2000-09-13 | Derives d'acides phosphoniques presentant une activite inhibitrice de carboxypeptidase b |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014615A true BR0014615A (pt) | 2002-06-18 |
Family
ID=26544854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014615-3A BR0014615A (pt) | 1999-09-14 | 2000-09-13 | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b |
Country Status (14)
Country | Link |
---|---|
US (2) | US6576627B1 (pt) |
EP (2) | EP1152004B1 (pt) |
JP (1) | JP3400798B2 (pt) |
KR (1) | KR100681632B1 (pt) |
CN (1) | CN1187360C (pt) |
AT (1) | ATE239741T1 (pt) |
AU (1) | AU780542B2 (pt) |
BR (1) | BR0014615A (pt) |
CA (1) | CA2381801C (pt) |
DE (1) | DE60002558T2 (pt) |
ES (1) | ES2202171T3 (pt) |
MX (1) | MXPA02002671A (pt) |
TW (1) | TWI223651B (pt) |
WO (1) | WO2001019836A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
US6713496B2 (en) | 2002-01-22 | 2004-03-30 | Pfizer Inc | 3-(imidazolyl)-2-alkoxypropanoic acids |
JP2005516972A (ja) | 2002-01-22 | 2005-06-09 | ファイザー・インク | 血栓疾患の治療のためのtafi−a阻害剤として使用される3−(イミダゾリル)−2−アミノプロピオン酸 |
CA2714873A1 (en) * | 2002-03-21 | 2003-10-02 | Schering Aktiengesellschaft | Plasma carboxypeptidase b inhibitors |
EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
AU2003266713A1 (en) * | 2002-10-01 | 2004-05-04 | Meiji Seika Kaisha, Ltd. | Intermediate for producing carboxypeptidase b inhibitor |
US8067187B2 (en) | 2005-07-13 | 2011-11-29 | Crossbeta Biosciences B.V. | Cross-β structure binding compounds |
US8114832B2 (en) | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
US7820323B1 (en) | 2006-09-07 | 2010-10-26 | The United States Of America As Represented By The Secretary Of The Army | Metal borate synthesis process |
US7833660B1 (en) | 2006-09-07 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Army | Fluorohaloborate salts, synthesis and use thereof |
CA2741783A1 (en) | 2008-10-29 | 2010-05-06 | Taisho Pharmaceutical Co., Ltd. | Compounds having tafia inhibitory activity |
CN103140483B (zh) | 2010-07-15 | 2015-06-24 | 拜耳知识产权有限责任公司 | 作为杀虫剂的新杂环化合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE212739C (pt) | ||||
US4452791A (en) | 1982-03-15 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
US4560680A (en) | 1982-03-15 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
US4616005A (en) | 1982-06-23 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
JPS63215686A (ja) * | 1987-03-03 | 1988-09-08 | Mitsubishi Kasei Corp | アミノエチルホスフイン酸誘導体 |
US5030732A (en) * | 1988-03-03 | 1991-07-09 | Merck & Co., Inc. | Aminoethylphosphinic acid derivatives |
JP2001515013A (ja) | 1997-08-14 | 2001-09-18 | デパートメント オブ ジ アーミー, ユー.エス. ガバメント | 網膜病変および脊髄傷害の処置または予防 |
US6121252A (en) | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
AR023819A1 (es) | 1999-05-03 | 2002-09-04 | Astrazeneca Ab | FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION |
SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2000
- 2000-09-13 KR KR1020027003321A patent/KR100681632B1/ko not_active IP Right Cessation
- 2000-09-13 JP JP2001523413A patent/JP3400798B2/ja not_active Expired - Fee Related
- 2000-09-13 EP EP00960970A patent/EP1152004B1/en not_active Expired - Lifetime
- 2000-09-13 DE DE60002558T patent/DE60002558T2/de not_active Expired - Lifetime
- 2000-09-13 WO PCT/JP2000/006248 patent/WO2001019836A1/ja active IP Right Grant
- 2000-09-13 AT AT00960970T patent/ATE239741T1/de not_active IP Right Cessation
- 2000-09-13 MX MXPA02002671A patent/MXPA02002671A/es active IP Right Grant
- 2000-09-13 BR BR0014615-3A patent/BR0014615A/pt not_active IP Right Cessation
- 2000-09-13 CA CA002381801A patent/CA2381801C/en not_active Expired - Fee Related
- 2000-09-13 ES ES00960970T patent/ES2202171T3/es not_active Expired - Lifetime
- 2000-09-13 AU AU73112/00A patent/AU780542B2/en not_active Ceased
- 2000-09-13 CN CNB008127913A patent/CN1187360C/zh not_active Expired - Fee Related
- 2000-09-13 EP EP01125712A patent/EP1174434A1/en not_active Withdrawn
- 2000-09-13 US US09/926,125 patent/US6576627B1/en not_active Expired - Fee Related
- 2000-09-14 TW TW089118781A patent/TWI223651B/zh not_active IP Right Cessation
-
2002
- 2002-10-07 US US10/265,400 patent/US6737416B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1152004A1 (en) | 2001-11-07 |
CA2381801C (en) | 2009-12-08 |
US20030119787A1 (en) | 2003-06-26 |
TWI223651B (en) | 2004-11-11 |
EP1152004B1 (en) | 2003-05-07 |
CN1187360C (zh) | 2005-02-02 |
JP3400798B2 (ja) | 2003-04-28 |
MXPA02002671A (es) | 2002-07-30 |
ATE239741T1 (de) | 2003-05-15 |
DE60002558T2 (de) | 2004-04-08 |
US6576627B1 (en) | 2003-06-10 |
DE60002558D1 (de) | 2003-06-12 |
CN1373766A (zh) | 2002-10-09 |
WO2001019836A1 (fr) | 2001-03-22 |
US6737416B2 (en) | 2004-05-18 |
ES2202171T3 (es) | 2004-04-01 |
EP1152004A4 (en) | 2002-01-23 |
AU780542B2 (en) | 2005-03-24 |
CA2381801A1 (en) | 2001-03-22 |
AU7311200A (en) | 2001-04-17 |
KR20020026268A (ko) | 2002-04-06 |
KR100681632B1 (ko) | 2007-02-09 |
EP1174434A1 (en) | 2002-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0014615A (pt) | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b | |
NO324249B1 (no) | Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene | |
TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
TWI265929B (en) | Triazinyl derivatives for inhibiting the production of IL-12 | |
BR9811521A (pt) | Composição para tratar ou impedir a glomerulopatia | |
IT1311922B1 (it) | Composti farmaceutici. | |
BR0113389A (pt) | Compostos que inibem a atividade do fator xa | |
IL136100A0 (en) | Biphenylamidine derivatives, prodrugs thereof and pharmaceutical compositions containing the same | |
DE69623497T2 (de) | 1-methylcarbapenem-derivate | |
NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
EP1252890A4 (en) | MEDICINAL AND PREVENTIVE AGENTS FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE COMPOUNDS | |
BR0206036A (pt) | Derivados de ácido benzóico substituìdos tendo ação de inibição de nf-kb | |
NO20012443D0 (no) | Benzoksazolderivater og legemidler inneholdende disse som aktiv bestanddel | |
HUP0000966A2 (hu) | Izoflavonszármazékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények | |
PT998930E (pt) | Composto azasteroide para o tratamento da alopecia hirsutismo ou seborreia | |
AU2001228862A1 (en) | Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives | |
HUP0301561A2 (hu) | Triazintrion-szulfoxidok alkalmazása kokcidiózis elleni készítmények elżállítására | |
NO993911L (no) | Remedier/Forebygningsmidler for Õndedrettssykdommer | |
DE60203029D1 (de) | Benzopyran Derivate und diese enthaltende Antiallergisches Mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B15Z | Prolongation of time limit refused |
Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO UMA VEZ QUE A MESMA NAO FOI APRESENTADA AO INPI NA VIGENCIA DO PRAZO PREVISTO PARA A PRATICA DO ATO, CONFORME DEFINIDO NO ART. 221 DA LPI E NO ART. 2O, PARAGRAFO UNICO, DA RESOLUCAO NO 116/04. A COPIA DO PARECER (DAS RAZOES) PODERA SER SOLICITADA ATRAVES DO FORMULARIO 1.05. (DESTA DATA CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO). |
|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2440 DE 10/10/2017. |